PSA response to Lu177-PSMA-617 in patients experiencing xerostomia and ocular dryness in metastatic castration resistant prostate cancer.

R Rebecca Hassoun (The Ohio State University College of Medicine, Columbus, OH) M Mark Tann (Indiana University School of Medicine, Indianapolis, IN) J Justin Sims (Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN) A Ashleigh Auxier (Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN) S Sandra K. Althouse (Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN) T Tareq Salous (Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN) J Jennifer King (Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN) N Nabil Adra (Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN)

Abstract

127 Background: Lu177-PSMA-617 (PSMA Lu177) therapy can cause dry mouth and/or eyes, as prostate specific membrane antigen (PSMA) is expressed in salivary and lacrimal glands. We evaluate the PSA response in pts with metastatic castration resistant prostate cancer (mCRPC) receiving PSMA-Lu177 who experienced dry mouth/eyes. Methods: The Indiana University Prostate Cancer database was queried for pts with mCRPC who were treated with PSMA Lu177. Adverse Events were documented throughout the course of treatment. PSA30 and PSA50 response were analyzed among subgroups of patients who had presence/absence of xerostomia and ocular dryness. Comparisons between the groups were based on the Chi Square test, or Fisher’s Exact test, if more appropriate. Results: 144 pts with mCRPC were treated with PSMA Lu177 between November 2022 and October 2024. Included pts received at least 2 doses. Median age was 74 (53, 91). 126 pts had metastatic disease in bone, 80 in pelvic lymph nodes, 27 lungs, 20 liver, and 5 brain. 58 pts had 1 prior ARPI, 86 pts had ≥2 prior ARPI. 28 pts had no prior taxane regimen, 116 had at least 1 prior taxane. 23 pts had prior PARP inhibitor. Median follow-up from start of PSMA Lu177 was 9.77 months (1.38-26.9). 62 (43.1%) pts experienced dry mouth, 15 (10.4%) experienced dry eyes, and 13 (9%) experienced both. 92 (63.9%) pts achieved PSA30 response, and 81 (56.3%) achieved PSA 50 response. Conclusions: Patients with mCRPC treated with PSMA Lu177 who reported dry mouth were more likely to experience PSA responses. Number and % of Pts Achieving PSA30 and PSA50 Response Characteristic (N) PSA30 response, N (%) PSA30 p-value PSA50 response, N (%) PSA50 p-value Dry mouth Present (N=62) Absent (N=82) 49 (79%)43 (52.4%) 0.0010 41 (66.1%)40 (48.8%) 0.0377 Dry eyes Present (N=15) Absent (N=129) 11 (73.3%)81 (62.8%) 0.4211 8 (53.3%)73 (56.6%) 0.8099 Dry eyes and/or dry mouth Present (N=64) Absent (N=80) 51 (79.7%)41 (51.3%) 0.0004 43 (67.2%)38 (47.5%) 0.0180

Article Details

Volume / Issue Vol. 43, Issue 5_suppl
Published February 10, 2025
Pages 127-127
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (8)

R

Rebecca Hassoun

The Ohio State University College of Medicine, Columbus, OH

M

Mark Tann

Indiana University School of Medicine, Indianapolis, IN

J

Justin Sims

Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN

A

Ashleigh Auxier

Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN

S

Sandra K. Althouse

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN

T

Tareq Salous

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN

J

Jennifer King

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN

N

Nabil Adra

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN